There are currently 1259 clinical trials in Columbus, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Nationwide Children's Hospital, Ohio State University Comprehensive Cancer Center, Ohio State University and The Ohio State University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Janus Feasibility Study
NCT03985527
Recruiting
The purpose of this feasibility study is to assess whether an alternative transvenous lead location affects respiration and airway physiology during a commercial remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator) implant procedure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Sleep Apnea Syndromes
Register for Updates
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
NCT06209619
Recruiting
This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal response early on to CAR T-cell therapy. Immunotherapy with CC-99282 may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Rituximab is a monoclonal antibody. It binds to a protein called CD... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent, High Grade B-Cell Lymphoma-Recurrent, Primary Mediastinal Large B-Cell Lymphoma-Recurrent, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory, Diffuse Large B-Cell Lymphoma-Refractory, Follicular Lymphoma-Refractory, High Grade B-Cell Lymphoma-Refractory, Primary Mediastinal Large B-Cell Lymphoma-Refractory, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory
Register for Updates
Open Versus Arthroscopic Stabilization of Shoulder Instability with Subcritical Bone Loss: the OASIS Trial
NCT04809064
Recruiting
This clinical trial will investigate the effects of three surgical procedures and the associated post-operative rehabilitation to optimize time to return to military duty, work and sports, and patient-reported physical function for military personnel and civilians with traumatic anterior shoulder instability and 10-20% glenoid bone loss.
Gender:
ALL
Ages:
Between 17 years and 50 years
Trial Updated:
10/08/2024
Locations: Ohio State University, Wexner Medical Center, Columbus, Ohio
Conditions: Shoulder Dislocation, Glenohumeral Dislocation, Anterior Shoulder Dislocation
Register for Updates
A Low-Insulinemic Dietary Intervention to Reduce Breast Cancer Risk in High-Risk Women
NCT06635005
Recruiting
This clinical trial tests whether a new dietary pattern that consists of foods that lower the blood insulin response can reduce breast cancer risk in high-risk women. In a large group of patients, this new dietary pattern was associated with reduced risk of multiple cancers and reduced risk of long-term weight gain. Parts of this new dietary pattern are quite different from typical dietary recommendations, and much education is needed. Overall, compared to the typical American diet, this new die... Read More
Gender:
FEMALE
Ages:
45 years and above
Trial Updated:
10/08/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Feasibility Pilot Study, Compliance
Register for Updates
A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy
NCT06378398
Recruiting
This trial will obtain biomarker data on the possible preventive effects of omeprazole and low-dose aspirin in colorectal tissue. Persons who have had 5 or more adenomas, 5 or more serrated polyps, or an incompletely removed adenoma or serrated polyp in the colon or rectum are potentially eligible. Before participating in the study, study staff will explain the study and review the consent form. If you are interested and provide consent, study staff will then confirm your eligibility. Once enrol... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/08/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Colorectal Neoplasia
Register for Updates
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
NCT03975231
Recruiting
This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving dabrafenib, trametinib, and IMRT together may kill more tumor cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
Register for Updates
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
NCT06158958
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy and in combination with budigalimab, (ABBV-181). ABBV-303 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-303 as a single agent or in combination with bud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: The Ohio State University - The James /ID# 260475, Columbus, Ohio
Conditions: Solid Tumors
Register for Updates
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
NCT04697576
Recruiting
This phase I trial investigates the effects of influenza vaccine in treating patients with stage I-IV melanoma. While intramuscular administration of influenza vaccine provides immunization against the influenza virus, giving influenza vaccine directly into the tumor (intralesional) may decrease the size of the injected melanoma tumor, or the extent of the melanoma within the body.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/06/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Register for Updates
A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors
NCT06630429
Recruiting
We propose to conduct a pilot study evaluating baseline and on-treatment changes in tumor fraction (TFx) in peripheral blood in patients with NSCLC and RCC being treated with checkpoint inhibitor therapy as part of standard of care. The primary objective of the study is to determine whether baseline TFx can be reliably predicted in patients with NSCLC and RCC and if changes can be detected during treatment that may correlate with response. Exploratory analyses will be completed to assess the pot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)
Register for Updates
Feasibility of Aerodigestive Stimulation Therapy Trial
NCT06118697
Recruiting
The goal of this study is to demonstrate safety, feasibility, and efficacy of a novel pharyngo-esophageal stimulation technique in restoring aerodigestive and swallowing functions in select infants at-risk for chronic gavage tube feeding or gastrostomy. The main aims are: * To provide consistent activation of deglutition (the process of swallowing), swallowing-airway interactions, and peristalsis in order to decrease the risk of home tube feeding. * To examine whether physical and manometric ev... Read More
Gender:
ALL
Ages:
Between 1 day and 8 months
Trial Updated:
10/03/2024
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Feeding Disorder Neonatal
Register for Updates
GERD Infant Feeding Therapeutics Trial (GIFT Trial)
NCT06114836
Recruiting
The goal of this investigator-initiated, single-center, randomized controlled trial (RCT) is to compare the effects of four weeks of three therapies on clinical and mechanistic outcomes based on pH-Imp testing using a three-arm parallel design in NICU infants with objective GERD diagnosis. The three therapies being compared are natural maturation, proton pump inhibitor (PPI) use, and added rice (AR) formula use. The main goals are: * to evaluate and compare the efficacy of the three commonly us... Read More
Gender:
ALL
Ages:
Between 1 day and 8 months
Trial Updated:
10/03/2024
Locations: Nationwide Children's Hospita, Columbus, Ohio
Conditions: GERD in Infants
Register for Updates
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
NCT06160752
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: The Ohio State University, Columbus, Ohio
Conditions: Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Register for Updates